Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
AIMS: galectin-3 is an emerging biomarker which has been studied in relatively small heart failure (HF) cohorts with predominantly systolic HF. We studied the prognostic value of base-line galectin-3 in a large HF cohort, with preserved and reduced left ventricular ejection fraction (LVEF), and compared this to other biomarkers. METHODS: we studied 592 HF patients who had been hospitalized for HF and were followed for 18 months. The primary end-point was a composite of all-cause mortality and HF hospitalization. RESULTS: a doubling of galectin-3 levels was associated with a hazard ratio (HR) of 1.97 (1.62-2.42) for the primary outcome (P < 0.001). After correction for age, gender, BNP, eGFR, and diabetes the HR was 1.38 (1.07-1.78; P = 0.015). Galectin-3 levels were correlated with higher IL-6 and CRP levels (P < 0.002). Changes of galectin-3 levels after 6 months did not add prognostic information to the base-line value (n = 291); however, combining plasma galectin-3 and BNP levels increased prognostic value over either biomarker alone (ROC analysis, P < 0.05). The predictive value of galectin-3 was stronger in patients with preserved LVEF (n = 114) compared to patients with reduced LVEF (P < 0.001). CONCLUSIONS: galectin-3 is an independent marker for outcome in HF and appears to be particularly useful in HF patients with preserved LVEF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
Dickstein, K., Authors/Task Force Members, Cohen-Solal, A., Filippatos, G., McMurray, J. J. V., Ponikowski, P., Poole-Wilson, P. A., Strömberg, A., van Veldhuisen, D. J., Atar, D., et al. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.08.005 · Cited by 3,512
Self-citationYusuf, S., Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J., Michelson, E. L., Olofsson, B., & Östergren, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14285-7 · Cited by 2,994
Authors/Task Force Members, Dickstein, K., Cohen-Solal, A., Filippatos, G., McMurray, J. J. V., Ponikowski, P., Poole-Wilson, P. A., Stromberg, A., van Veldhuisen, D. J., Atar, D., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn309 · Cited by 2,696
Self-citationPaulus, W. J., Tschöpe, C., Sanderson, J. E., Rusconi, C., Flachskampf, F. A., Rademakers, F. E., Marino, P., Smiseth, O. A., De Keulenaer, G., Leite-Moreira, A. F., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm037 · Cited by 2,679
Sharma, U. C., Pokharel, S., van Brakel, T. J., van Berlo, J. H., Cleutjens, J. P. M., Schroen, B., André, S., Crijns, H. J. G. M., Gabius, H. J., Maessen, J., et al. (2004) · Circulation · doi:10.1161/01.cir.0000147181.65298.4d · Cited by 947
Galectins: structure, function and therapeutic potential
Yang, R.-Y., Rabinovich, G. A., & Liu, F.-T. (2008) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399408000719 · Cited by 862
Plasma Cytokine Parameters and Mortality in Patients With Chronic Heart Failure
Rauchhaus, M., Doehner, W., Francis, D. P., Davos, C., Kemp, M., Liebenthal, C., Niebauer, J., Hooper, J., Volk, H.-D., Coats, A. J. S., et al. (2000) · Circulation · doi:10.1161/01.cir.102.25.3060 · Cited by 810
Kondo, M. A., Tajinda, K., Colantuoni, C., Hiyama, H., Seshadri, S., Huang, B., Pou, S., Furukori, K., Hookway, C., Peled, H. J., et al. (2012) · Cited by 655
van Kimmenade, R. R., Januzzi, J. L., Ellinor, P. T., Sharma, U. C., Bakker, J. A., Low, A. F., Martinez, A., Crijns, H. J., MacRae, C. A., Menheere, P. P., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.03.061 · Cited by 567
Galectin-3: A Novel Mediator of Heart Failure Development and Progression
de Boer, R. A., Voors, A. A., Muntendam, P., van Gilst, W. H., & van Veldhuisen, D. J. (2009) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfp097 · Cited by 524
Self-citation
Cited by
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.025 · Cited by 3,418
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31829e8807 · Cited by 3,304
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000509 · Cited by 3,109
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31829e8776 · Cited by 2,106
Frangogiannis, N. G. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa324 · Cited by 1,229
Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities
Frangogiannis, N. G. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.07.001 · Cited by 841
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2017.04.014 · Cited by 770
Chow, S. L., Maisel, A. S., Anand, I., Bozkurt, B., de Boer, R. A., Felker, G. M., Fonarow, G. C., Greenberg, B., Januzzi, J. L., Kiernan, M. S., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000490 · Cited by 601
Self-citationGalectin-3, a Marker of Cardiac Fibrosis, Predicts Incident Heart Failure in the Community
Ho, J. E., Liu, C., Lyass, A., Courchesne, P., Pencina, M. J., Vasan, R. S., Larson, M. G., & Levy, D. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.04.053 · Cited by 589
Yu, L., Ruifrok, W. P. T., Meissner, M., Bos, E. M., van Goor, H., Sanjabi, B., van der Harst, P., Pitt, B., Goldstein, I. J., Koerts, J. A., et al. (2013) · Circulation: Heart Failure · doi:10.1161/circheartfailure.112.971168 · Cited by 435
Self-citationBiomarkers and diagnostics in heart failure
Gaggin, H. K., & Januzzi, J. L. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.12.014 · Cited by 423
Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z
Sciacchitano, S., Lavra, L., Morgante, A., Ulivieri, A., Magi, F., De Francesco, G., Bellotti, C., Salehi, L., & Ricci, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020379 · Cited by 377
The fibrosis marker galectin‐3 and outcome in the general population
de Boer, R. A., van Veldhuisen, D. J., Gansevoort, R. T., Muller Kobold, A. C., van Gilst, W. H., Hillege, H. L., Bakker, S. J. L., & van der Harst, P. (2012) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2011.02476.x · Cited by 376
Self-citationDeveloping Therapies for Heart Failure With Preserved Ejection Fraction
Butler, J., Fonarow, G. C., Zile, M. R., Lam, C. S., Roessig, L., Schelbert, E. B., Shah, S. J., Ahmed, A., Bonow, R. O., Cleland, J. G. F., et al. (2014) · JACC: Heart Failure · doi:10.1016/j.jchf.2013.10.006 · Cited by 324
The fibrosis-cell death axis in heart failure
Piek, A., de Boer, R. A., & Silljé, H. H. W. (2016) · Heart Failure Reviews · doi:10.1007/s10741-016-9536-9 · Cited by 301
Self-citation2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.020 · Cited by 288
Immune Mechanisms in Heart Failure
Zhang, Y., Bauersachs, J., & Langer, H. F. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.942 · Cited by 262
Bayes-Genis, A., de Antonio, M., Vila, J., Peñafiel, J., Galán, A., Barallat, J., Zamora, E., Urrutia, A., & Lupón, J. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.087 · Cited by 259
Association of sST2 and hs-CRP levels with new-onset atrial fibrillation in coronary artery disease
Nortamo, S., Ukkola, O., Lepojärvi, S., Kenttä, T., Kiviniemi, A., Junttila, J., Huikuri, H., & Perkiömäki, J. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.07.022 · Cited by 65
Galectin-3 increase in endurance athletes
Hättasch, R., Spethmann, S., de Boer, R. A., Ruifrok, W. P., Schattke, S., Wagner, M., Schroeckh, S., Durmus, T., Schimke, I., Sanad, W., et al. (2014) · European Journal of Preventive Cardiology · doi:10.1177/2047487313492069 · Cited by 46
Metadata
- Authors
- de Boer, R. A., Lok, D. J. A., Jaarsma, T., van der Meer, P., Voors, A. A., Hillege, H. L., & van Veldhuisen, D. J.
- Venue
- Annals of Medicine
- Publisher
- Informa UK Limited
- Published
- 2010-12-28
- Volume
- 43
- Issue
- 1
- Pages
- 60-68
- ISSN
- 0785-3890 (ISSN-L)
- 1365-2060
- OpenAlex
- W2015404118
- Cited by
- 592
- References
- 32
- FWCI
- 20.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.